It is interesting that the NSCLC cell lines resistant to EGFR-TKI respond to the PI3K inhibitor and that the increase of pERK1/2, likely induced by the activation of feedback loops, is controlled by gefitinib in the combination treatment. The gene discussed is PIK3CA; the disease is non-small cell lung carcinoma.